### Overview
Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

### Coverage Guidelines
1. **Patient Population**
   - AllWays Health Partners may authorize coverage of Spinraza (nusinersen) for members, when ALL of the following criteria are met:
     - Members have a documented diagnosis of spinal muscular atrophy (SMA) type 1, 2, or 3 confirmed by molecular genetic testing
     - Clinical documentation of baseline (pre-treatment) motor function skills has been submitted
     - Members have already established care with a SMA multidisciplinary care center
     - Members have none of the following: hospitalization for surgery or pulmonary event within past 2 months, active infection, brain or spinal cord disease, meningitis, implanted CSF shunt, treatment with another investigational drug <1 month of evaluation

2. **Prescribing**
   - Prescribed by neurologist with expertise in the management of SMA

3. **Dosing and Administration**
   - 4 loading doses: First 3 loading doses at 14 day intervals, 4th loading dose 30 days after 3rd dose
   - Maintenance dose every 4 months after the 4th loading dose
- Dose: 12 mg (5 mL) given intrathecally as bolus injection over 1-3 minutes using a spinal anesthesia needle
- Prior to administration, remove 5 mL of cerebral spinal fluid (CSF)
- Administered by attending neurologist experienced in administering intrathecal injections

4. Monitoring
- At baseline and prior to each dose, obtain a platelet count, coagulation test (i.e., prothrombin time, activated partial thromboplastin time) and quantitative spot urine protein test
- At each visit, assessment for improvement in clinical outcomes via motor function using HINE, CHOP-INTEND, HFMSE or other age-appropriate motor function scales

5. Duration of Therapy
- May be continued until disease progression or unacceptable toxicity (may require several months to a year for improvement in motor function to be seen)
- Discontinuation of drug to be determined based on age-appropriate performance on motor function and patient reported outcome scales using standardized instrument(s)

Continuation of Therapy
Reauthorization requires physician documentation of assessment of improvement in clinical outcomes via motor function using HINE, CHOP-INTEND, HFMSE or other age-appropriate motor function scale.

Limitations
1. Approvals will be granted for 12 months.

References


**Review History**

02/2017 – Reviewed by Clinical Experts
08/2017 – Revised (P&T approval)
11/2019 – Reviewed

**Disclaimer**

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.